Friday, Aug 14, 2020 | Last Update : 08:32 PM IST

142nd Day Of Lockdown

Maharashtra54831338184318650 Tamil Nadu3145202563135278 Andhra Pradesh2641421709242378 Karnataka1964941126333511 Delhi1494601343184167 Uttar Pradesh140775887862280 West Bengal98459671202059 Telangana8647563074665 Bihar8274154139450 Gujarat71064542382652 Assam5883842326145 Rajasthan5249738235789 Odisha4592731785321 Haryana4163534781483 Madhya Pradesh3902529020996 Kerala3811424922127 Jammu and Kashmir2489717003472 Punjab2390315319586 Jharkhand185168998177 Chhatisgarh12148880996 Uttarakhand96326134125 Goa871259575 Tripura6161417641 Puducherry5382320187 Manipur3752204411 Himachal Pradesh3371218114 Nagaland30119738 Arunachal Pradesh223115923 Chandigarh1595100425 Meghalaya11154986 Sikkim9105101 Mizoram6203230
  Decaf   10 Dec 2017  Cancer cure: Made in India— a cancer curing drug molecule

Cancer cure: Made in India— a cancer curing drug molecule

Published : Dec 10, 2017, 2:39 am IST
Updated : Dec 10, 2017, 2:39 am IST

Results of the study approved by the Depart-ment of Biotech-nology will decide when the drug will be available in the market.

Perfect synthesis: Dr Sathees Raghavan and his team of researchers at Department of Biochemistry, Indian Institute of Science, Bengaluru.
 Perfect synthesis: Dr Sathees Raghavan and his team of researchers at Department of Biochemistry, Indian Institute of Science, Bengaluru.

In a first, 24 researchers from several labs have designed and synthesised ‘Disarib’, a drug which induces the death of cancer cells, and carried out preliminary tests as well. It has been patented, a first for a home-grown drug, developed for targeted therapy of cancer.

Cancer biologists, chemists, clinicians, and specialists in bioinformatics, belonging to different labs, will soon pool their expertise for a multi-crore rupee project aptly titled ‘Glue Grant’, to carry out pre-clinical tests of the drug Disarib which brings about the death of cancer cells.


The Department of Biotechnology (DBT), New Delhi, has approved this collaborative effort to produce the first home-grown drug, which has been found to be better than the one (Codenamed ABT199) approved by the Food and Drug Administration (FDA) of the United States, for it does not set off any side effects.

Designed and synthesised by researchers from eight different research groups spread over labs in Mumbai, Thiruvananthapuram, Bengaluru, and with contributions from a couple of Indian scientists at the Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Disarib belongs to the class of “designer molecules” that zero in on rogue cells as part of the targeted therapy method to combat cancer. To start with, the efficacy will be checked out on cancer cells of patients suffering from leukaemia and lymphoma. Besides Disarib, new drugs with similar action against cancer cells will be tested for toxicity and efficacy as part of the new project, says Prof. Sathees Raghavan of the Department of Biochemistry, Indian Institute of Science, Bengaluru.


Prof. Raghavan says preliminary studies by his group show that the home-grown molecule gets better results than the one approved by the FDA in terms of elimination of cancer cells. And, it does so in significantly smaller doses, reducing further the chances of side effects. “The smaller size of the Disarib molecule, compared with ABT199, makes it easier for the drug to reach the cancerous cells where it can begin destroying the tumour,” adds his colleague Supriya Vartak. The results have been published in Biochemical Pharmacology.

Following a number of preliminary tests and analyses, the drug was tested in cancer cell lines, animal models, patient samples and more. The team even utilised a humanised model of tumour in mice for ovarian carcinoma, in addition to three independent mouse tumour models for investigating the tumour regression property of Disarib. The molecule was found effective against a range of cancers — leukaemia, lymphoma, breast cancer, ovarian cancer and colon cancer.


“In all the cases, our molecule performed better than ABT199, which is why we decided to patent this molecule,” said Prof. Raghavan.

Pharmaceutical companies have shown some interest, which is very encouraging, says Prof. Raghavan, though he cautions that results of the study approved by the DBT will decide when the drug will be available in the market.

The group has developed other inhibitors, too, some synthesised in the lab and some extracted from plants, and they will be tested as part of the new project though they are not as effective as Disarib.

Tags: cancer cells, food and drug administration (fda), disarib